Jacek Jassem - Publications#

Selected publications and book chapters

1. Jassem J., Begg A.C., Stewart F.A., Bartelink H.: Combined chemotherapy and radiotherapy. In: Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. Oxford University Press, Oxford, Tokyo, New York, 1995, 811-822.

1. Jassem J., Pieńkowski T., Płuzańska A., Jelic S., Gorbunova V., Mrsic-Krmpotic Z., Berzins J., Nagykalnai T., Wigler N., Renard J., Munier S., Weil C.; Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001; 19: 1707-1715. 204 cit.

2. Bonner J.A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. 2.323 cit.

3. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., Jassem J., Van de Velde C.J., Delozier T., Alvarez I., Del Mastro L., Ortmann O., Diedrich K., Coates A.S., Bajetta E., Holmberg S.B., Dodwell D., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Forbes J., Castiglione M., Stuart N., Stewart A., Fallowfield L.J., Bertelli G., Hall E., Bogle R.G., Carpentieri M., Colajori E., Subar M., Ireland E., Bliss J.M. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570. 531 cit.

4. Rosell R., Skrzypski M., Jassem E., Taron M., Bartolucci R., Sanchez J.J., Mendez P., Chaib I., Perez-Roca L., Szymanowska A., Rzyman W., Puma F., Kobierska-Gulida G., Farabi R., Jassem J. BRCA1: A novel prognostic factor in resected non-small cell lung cancer. PLoS ONE 2007; 11: e1129. 113 cit.

5. Skrzypski M., Jassem E., Taron M., Sanchez J. J., Mendez P., Rzyman W., Gulida G., Raz D., Jablons D., Provencios M., Massuti B., Chaib I., Perez-Roca L., Jassem J., Rosell R.: Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008; 15: 4794-4799. 63 cit.

6. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., André S., Piccart M., Campone M., Brain E., Macgrogan G., Petit T., Jassem J., Bibeau F., Blot E., Bogaerts J., Aguet M., Bergh J., Iggo R., Delorenzi M.: A stroma related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Med 2009; 15: 68-74. IF: 279 cit.

7. Roepman P., Jassem J., Smit E. F., Muley T., Niklinski J., van de Velde T., Witteveen A., Rzyman W., Floore A., Burgers S., Giaccone G., Meister M., Dienemann H., Skrzypski M., Kozlowski M., Mooi W. J., van Zandwijk N.: An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009; 15: 284-290. 77 cit.

8. Dziadziuszko R., Merrick D. T., Witta S. E., Mendoza A. D., Szostakiewicz B., Szymanowska A., Rzyman W., Dziadziuszko K., Jassem J., Bunn Jr P. A., Varella-Garcia M., Hirsch F. R.: Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28: 2174-2180. 71 cit.

10. Douillard J.-Y., Oliner K. S., Siena S., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., Rivera F., Kocákova I., Ruff P., Błasińska-Morawiec M., Smakal M., Canon J. L., Rother M., Williams R., Rong A., Wiezorek J., Sidhu R., Patterson S. D.: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034. 478 cit.